Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6691 to 6705 of 8901 results

  1. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  2. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development Reference number: GID-TA11044 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development Reference number: GID-TA11344 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development Reference number: GID-TA11401 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-TA11569 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued Reference number: GID-TA11522

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued

  9. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  10. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  14. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]

    In development Reference number: GID-TA11588 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development